Shuttle Pharma Files S-1 for Resale of 625K Shares After $2.5M Private Placement

TL;DR

**SHPH's S-1 for 625,156 resale shares from a recent private placement means potential dilution and selling pressure, so watch for price volatility as the company funds its Phase II trial and planned acquisition.**

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed an S-1 on November 18, 2025, to register for resale 625,156 shares of common stock. These shares are issuable upon the exercise of a pre-funded warrant, exercisable at a nominal price of $0.001, which was issued to an accredited investor in a private placement completed on November 4, 2025, generating approximately $2.5 million in gross proceeds for the company. SHPH will not receive any proceeds from the selling stockholder's resale of these shares. The company is a discovery and development stage pharmaceutical company focused on cancer therapies, with its lead candidate, Ropidoxuridine, having commenced a Phase II clinical study in brain cancer patients in October 2024. SHPH also disclosed a binding term sheet dated October 20, 2025, for a contemplated asset acquisition from 1542770 BC Ltd. ('Molecule'). The last reported sale price for SHPH common stock on November 17, 2025, was $1.92 per share, and the company had 1,603,285 shares outstanding as of that date.

Why It Matters

This S-1 filing signals a potential increase in SHPH's public float, as 625,156 shares from a recent private placement are now registered for resale. For investors, this could introduce selling pressure on SHPH's stock, which closed at $1.92 on November 17, 2025, potentially impacting its market price. The company's ongoing Phase II clinical trial for Ropidoxuridine in brain cancer and the planned asset acquisition from Molecule are critical developments in a highly competitive oncology market, where successful drug development and strategic growth are paramount. Employees and customers will be watching for the impact of these financial and strategic moves on the company's long-term stability and product pipeline.

Risk Assessment

Risk Level: high — The filing explicitly states, 'An investment in our securities involves a high degree of risk.' Key risks include the potential adverse effect on the market price of common stock due to the resale of 625,156 shares by the selling stockholder, and risks associated with future acquisitions, such as the contemplated Asset Purchase from 1542770 BC Ltd., which could divert resources and management attention. Furthermore, the company's success is 'primarily dependent on the successful development, regulatory approval and commercialization of our product candidates, all of which are in the early stages of development.'

Analyst Insight

Investors should exercise caution due to the potential for increased selling pressure from the 625,156 shares registered for resale and the inherent risks of a clinical-stage biotech. Monitor SHPH's stock performance closely for signs of dilution-related volatility and track progress on the Ropidoxuridine Phase II trial and the Molecule asset acquisition, as these are critical for future value creation.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

Negative

total Assets

Undisclosed

total Debt

Undisclosed

net Income

Negative

eps

Negative

gross Margin

N/A

cash Position

Undisclosed

revenue Growth

N/A

Key Numbers

• 625,156 — Shares of common stock (Registered for resale by the selling stockholder, issuable upon exercise of a pre-funded warrant)
• $0.001 — Exercise price per share (Nominal exercise price for the pre-funded warrant)
• $2.5 million — Aggregate gross proceeds (Received by the company from the private placement on November 4, 2025)
• $1.92 — Last reported sale price per share (For SHPH common stock on November 17, 2025)
• 1,603,285 — Shares of common stock outstanding (As of November 17, 2025)
• 4% — Cash fee (Paid to WestPark Capital, Inc. as placement agent for the private placement)
• October 2024 — Commencement date (For the Phase II clinical study of Ropidoxuridine in brain cancer patients)
• November 4, 2025 — Closing date (For the private placement of the pre-funded warrant)
• October 20, 2025 — Date of binding term sheet (For the contemplated asset acquisition from 1542770 BC Ltd.)
• 47.1% — Percentage of shares beneficially owned after offering (By Alternative Investment Capital Inc., assuming all shares offered are sold and no other shares are acquired or sold)

Key Players & Entities

• Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant and pharmaceutical company
• Christopher Cooper (person) — Interim Chief Executive Officer
• Alternative Investment Capital Inc. (company) — Selling stockholder
• Connor Yuen (person) — Individual with voting and dispositive power over selling stockholder's shares
• WestPark Capital, Inc. (company) — Placement agent for the private placement
• 1542770 BC Ltd. (company) — Target for contemplated asset acquisition (Molecule)
• SEC (regulator) — Securities and Exchange Commission
• FDA (regulator) — Food and Drug Administration
• Sullivan & Worcester LLP (company) — Legal counsel
• The Nasdaq Capital Market (company) — Stock exchange where SHPH is listed

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company is in the discovery and development stage and has not generated significant revenue. It will require substantial additional capital to fund its ongoing operations, including clinical trials and potential commercialization. Failure to secure adequate funding could jeopardize its ability to continue as a going concern.
• Clinical Trial Risks and Delays [high — regulatory]: The success of Ropidoxuridine, the lead candidate, is dependent on the successful completion of Phase II clinical studies, which commenced in October 2024. Delays or adverse results in these trials could significantly impact the company's development timeline and financial projections.
• Reliance on Key Personnel [medium — operational]: The company's success is heavily reliant on its management team and scientific advisors. The loss of key personnel could disrupt research and development efforts and strategic planning.
• Competition in Cancer Therapies [medium — market]: The pharmaceutical market, particularly for cancer therapies, is highly competitive. SHPH faces competition from established pharmaceutical companies and emerging biotechs with potentially more advanced or effective treatments.
• Limited Operating History and No Revenue [high — financial]: As a development-stage company, SHPH has a limited operating history and has not generated any significant revenue to date. This lack of commercial traction increases the inherent risks associated with its business model.
• Intellectual Property Risks [medium — legal]: The company's ability to protect its intellectual property is crucial. Challenges to its patents or proprietary technology could negatively impact its competitive position and future revenue streams.

Industry Context

Shuttle Pharmaceuticals Holdings operates in the highly competitive oncology drug development sector. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like SHPH focus on identifying unmet medical needs and developing novel therapies, often through targeted approaches like Ropidoxuridine for brain cancer.

Regulatory Implications

As a pharmaceutical developer, SHPH is subject to stringent regulations by bodies like the FDA. The success of its lead candidate hinges on navigating complex clinical trial protocols and demonstrating safety and efficacy. Any adverse findings or regulatory delays could significantly impact its path to market.

What Investors Should Do

1. Monitor Phase II Trial Results
2. Assess Funding Needs and Sources
3. Evaluate Asset Acquisition Impact
4. Analyze Shareholder Dilution

Key Dates

• 2025-11-18: S-1 Filing — Registers shares for resale by a selling stockholder, providing liquidity for an early investor and indicating potential market interest.
• 2025-11-04: Private Placement Closing — Raised approximately $2.5 million in gross proceeds for the company, demonstrating continued investor confidence in its development pipeline.
• 2025-10-20: Binding Term Sheet for Asset Acquisition — Indicates a strategic move towards expanding the company's asset base, potentially accelerating its development or commercialization efforts.
• 2024-10-01: Phase II Clinical Study Commencement — Marks a critical milestone in the development of Ropidoxuridine, moving the lead candidate closer to potential market approval.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (Provides comprehensive disclosure of SHPH's business, risks, and the details of the shares being registered for resale.)

Pre-funded Warrant

A type of warrant that allows the holder to purchase shares at a nominal price, often used in private placements to avoid immediate dilution and provide a more immediate economic interest. (Explains the structure of the private placement, where 625,156 shares are issuable upon exercise of such a warrant at $0.001.)

Discovery and Development Stage Pharmaceutical Company

A company focused on researching and developing new drugs or therapies, which typically has no approved products and has not generated significant revenue. (Defines SHPH's current business status, highlighting its reliance on future clinical success and funding.)

Phase II Clinical Study

A stage of clinical research in humans designed to evaluate the effectiveness of a drug or treatment for a specific condition and to further assess its safety. (Indicates the current stage of development for SHPH's lead candidate, Ropidoxuridine, in brain cancer patients.)

Binding Term Sheet

A preliminary, non-binding or binding agreement that outlines the key terms and conditions of a proposed transaction, such as an acquisition. (Signals a significant potential transaction for SHPH, an asset acquisition from 1542770 BC Ltd.)

Year-Over-Year Comparison

This S-1 filing does not provide comparative financial data from a previous year as it is an initial registration for resale of shares. The company is in the discovery and development stage, with no reported revenue in prior periods. Key developments since the last reporting period include the commencement of a Phase II clinical study for Ropidoxuridine in October 2024 and the execution of a binding term sheet for an asset acquisition in October 2025, indicating progress in its development pipeline and strategic growth.

Key Financial Figures

• $0 — t a nominal exercise price per share of $0.001, without expiration. The pre-funded
• $1.92 — ted sale price for our common stock was $1.92 per share. Investing in our common st
• $2.5 million — gregate gross proceeds of approximately $2.5 million. The private placement closed on Novemb
• $3.599 — k of the Company at a purchase price of $3.599 and exercise price of $0.001 per pre-fu
• $0.001 — e price of $3.599 and exercise price of $0.001 per pre-funded warrant (the “June
• $4.3 million — eceived gross proceeds of approximately $4.3 million before deducting fees and other offerin

Filing Documents

• forms-1.htm (S-1) — 231KB
• ex5-1.htm (EX-5.1) — 13KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 24KB
• ex5-1_001.jpg (GRAPHIC) — 6KB
• ex5-1_002.jpg (GRAPHIC) — 2KB
• 0001493152-25-024089.txt ( ) — 407KB
• ex107_htm.xml (XML) — 7KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 6

USE OF PROCEEDS

USE OF PROCEEDS 6 SELLING STOCKHOLDER 7 PLAN OF DISTRIBUTION 8 LEGAL MATTERS 9 EXPERTS 9 INFORMATION INCORPORATED BY REFERENCE 10 WHERE YOU CAN FIND MORE INFORMATION 10 3 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we have filed with the SEC pursuant to which the selling stockholder named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered by this prospectus. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or shares of common stock are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under “Where You Can Find More Information” and “Information Incorporated by Reference” in this prospectus. We have not authorized anyone to give any information or to make any representation to you other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our shares of common stock other than the shares of our common stock covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in

View Full Filing

View this S-1 filing on SEC EDGAR